Trials / Conditions / Refractory Primary Central Nervous System Lymphoma
Refractory Primary Central Nervous System Lymphoma
3 registered clinical trials studyying Refractory Primary Central Nervous System Lymphoma — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) NCT07082868 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) NCT04947319 | Ono Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractor NCT03328078 | Curis, Inc. | Phase 1 / Phase 2 |